Literature DB >> 8163710

Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development.

C C Peck1, W H Barr, L Z Benet, J Collins, R E Desjardins, D E Furst, J G Harter, G Levy, T Ludden, J H Rodman.   

Abstract

Mesh：

Substances：

Year:  1994        PMID： 8163710     DOI： 10.1002/j.1552-4604.1994.tb03974.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN： 0091-2700            Impact factor:   3.126


× No keyword cloud information.
  13 in total

1.  Modeling of pharmacokinetic/pharmacodynamic (PK/PD) relationships: concepts and perspectives.

Authors:  H Derendorf; B Meibohm
Journal:  Pharm Res       Date:  1999-02       Impact factor: 4.200

Review 2.  Pharmacokinetics/Pharmacodynamics and the stages of drug development: role of modeling and simulation.

Authors:  Jenny Y Chien; Stuart Friedrich; Michael A Heathman; Dinesh P de Alwis; Vikram Sinha
Journal:  AAPS J       Date:  2005-10-07       Impact factor: 4.009

3.  Model-based drug development: the road to quantitative pharmacology.

Authors:  Liping Zhang; Vikram Sinha; S Thomas Forgue; Sophie Callies; Lan Ni; Richard Peck; Sandra R B Allerheiligen
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-06-13       Impact factor: 2.745

4.  Novel hybrid GPU-CPU implementation of parallelized Monte Carlo parametric expectation maximization estimation method for population pharmacokinetic data analysis.

Authors:  C M Ng
Journal:  AAPS J       Date:  2013-09-04       Impact factor: 4.009

Review 5.  Expanding clinical applications of population pharmacodynamic modelling.

Authors:  C Minto; T Schnider
Journal:  Br J Clin Pharmacol       Date:  1998-10       Impact factor: 4.335

6.  Population pharmacokinetics and pharmacodynamics: potential use for gathering dose-concentration-response.

Authors:  M Jerling
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1996 Apr-Jun       Impact factor: 2.441

Review 7.  Model-based clinical drug development in the past, present and future: a commentary.

Authors:  Holly Kimko; José Pinheiro
Journal:  Br J Clin Pharmacol       Date:  2015-01       Impact factor: 4.335

Review 8.  Transitioning from Basic toward Systems Pharmacodynamic Models: Lessons from Corticosteroids.

Authors:  Vivaswath S Ayyar; William J Jusko
Journal:  Pharmacol Rev       Date:  2020-04       Impact factor: 25.468

Review 9.  Should patients be given an initial low test dose of sildenafil?

Authors:  J S Cohen
Journal:  Drug Saf       Date:  2000-07       Impact factor: 5.606

10.  Improving data reliability using a non-compliance detection method versus using pharmacokinetic criteria.

Authors:  Smita A Kshirsagar; Terrence F Blaschke; Lewis B Sheiner; M Krygowski; Edward P Acosta; Davide Verotta
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-09-27       Impact factor: 2.745
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.